ATE416784T1 - Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz - Google Patents

Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz

Info

Publication number
ATE416784T1
ATE416784T1 AT01998183T AT01998183T ATE416784T1 AT E416784 T1 ATE416784 T1 AT E416784T1 AT 01998183 T AT01998183 T AT 01998183T AT 01998183 T AT01998183 T AT 01998183T AT E416784 T1 ATE416784 T1 AT E416784T1
Authority
AT
Austria
Prior art keywords
bioactive substance
preparation
producing
solid material
amount
Prior art date
Application number
AT01998183T
Other languages
English (en)
Inventor
Yoshihiro Ohmachi
Masafumi Misaki
Shigeyuki Takada
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE416784T1 publication Critical patent/ATE416784T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01998183T 2000-12-01 2001-11-29 Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz ATE416784T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000367183 2000-12-01

Publications (1)

Publication Number Publication Date
ATE416784T1 true ATE416784T1 (de) 2008-12-15

Family

ID=18837665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998183T ATE416784T1 (de) 2000-12-01 2001-11-29 Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz

Country Status (8)

Country Link
US (2) US7090869B2 (de)
EP (2) EP2062593A3 (de)
JP (1) JP2009062389A (de)
AT (1) ATE416784T1 (de)
AU (1) AU2002224124A1 (de)
CA (1) CA2430934C (de)
DE (1) DE60136958D1 (de)
WO (1) WO2002043709A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10353856A1 (de) * 2003-11-18 2005-06-16 Goldschmidt Ag Emulgatorfreie Öl in Wasser-Emulsionen von Organopolysiloxanen und deren Verwendung in technischen Anwendungen
ATE349199T1 (de) * 2004-04-15 2007-01-15 Helm Ag Verfahren zur herstellung von freifliessenden, pulverförmigen valsartan-adsorbaten
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
AU2005264998A1 (en) * 2004-06-17 2006-01-26 Wyeth The present invention relates to methods of making Gonadotropin Releasing Hormone ('GnRH') (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists
KR20070027584A (ko) 2004-06-17 2007-03-09 와이어쓰 고나도트로핀 방출 호르몬 수용체 길항제
CA2587853A1 (en) * 2004-11-23 2006-06-01 Wyeth Gonadotropin releasing hormone receptor antagonists
US7538113B2 (en) * 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) * 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189619A1 (en) * 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
US7531542B2 (en) * 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US8945598B2 (en) * 2005-12-29 2015-02-03 Cordis Corporation Low temperature drying methods for forming drug-containing polymeric compositions
US20070158880A1 (en) * 2006-01-06 2007-07-12 Vipul Bhupendra Dave Methods of making bioabsorbable drug delivery devices comprised of solvent cast tubes
US20070160672A1 (en) * 2006-01-06 2007-07-12 Vipul Bhupendra Dave Methods of making bioabsorbable drug delivery devices comprised of solvent cast films
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8207236B2 (en) * 2006-05-23 2012-06-26 Ferro Corporation Method for the production of porous particles
US20080166436A1 (en) * 2007-01-10 2008-07-10 Apperon Inc. Composition for normalizing otitis externa in mammals
WO2008084504A2 (en) * 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
US11039707B2 (en) * 2007-05-17 2021-06-22 International Flavors & Fragrances Inc. Microencapsulated delivery system
US20090095164A1 (en) * 2007-05-17 2009-04-16 Salvatore Albert Celeste Method of enhancing beverages by means of a unique microencapsulated delivery system
WO2008156356A1 (en) * 2007-06-19 2008-12-24 Feyecon Development & Implementation B.V. Preparation of a pharmaceutically active ingredient comprising a desolventising step
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
GB0907251D0 (en) * 2009-04-28 2009-06-10 Univ Leiden Coplymers
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CN102665690A (zh) * 2009-12-22 2012-09-12 武田药品工业株式会社 缓释制剂
JP2012184364A (ja) * 2011-03-07 2012-09-27 Seiko Instruments Inc アクリル樹脂およびその製造方法
EP2758183B1 (de) 2011-09-18 2022-02-09 Bio Plasmar Ltd Bioabbaubarer blumentopf oder bioabbaubares essgeschirr
JP6068787B2 (ja) * 2011-09-30 2017-01-25 大王製紙株式会社 ティシュペーパーの製造方法
HK1207564A1 (en) 2012-04-19 2016-02-05 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
EP2727584A1 (de) * 2012-10-31 2014-05-07 Takeda GmbH Abgase zur Verwendung beim Trocknen, Lagern bzw. Rekonstituieren von Biomolekülen
HUE055348T2 (hu) 2012-11-20 2021-11-29 Opko Biologics Ltd Eljárás polipeptidek hidrodinamikus térfogatának növelésére gonadotropin karboxil-terminális peptidekhez való kapcsolással
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3230309B1 (de) 2014-12-10 2023-03-29 OPKO Biologics Ltd. Verfahren zur herstellung langwirkender ctp-modifizierter wachstumshormonpolypeptide
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
JP2017190424A (ja) * 2016-04-15 2017-10-19 竹本油脂株式会社 ビニル共重合体
US10844213B2 (en) * 2016-04-27 2020-11-24 Kuraray Co., Ltd. Acrylic thermoplastic resin composition, molded article, film and method for producing same, and laminate
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
FR3068977B1 (fr) * 2017-07-12 2020-09-04 Arkema France Composition comprenant un polymere a phases multiples et un polymere (meth)acrylique, son procede de preparation et son utilisation
EP3502180A1 (de) * 2017-12-19 2019-06-26 Chi Mei Corporation Polymethacrylatzusammensetzung und daraus hergestellte optische vorrichtung sowie anzeigevorrichtung
JP7670487B2 (ja) * 2018-11-15 2025-04-30 三菱ケミカル株式会社 導電性組成物及びその製造方法と、導電体及びその製造方法
EP3904453B1 (de) 2018-12-27 2023-05-10 Kaneka Corporation Harzzusammensetzung und verwendung davon
CN113646382B (zh) 2019-03-28 2024-12-03 株式会社钟化 树脂组合物的制造方法及树脂组合物
EP3950749A4 (de) * 2019-03-28 2022-12-21 Kaneka Corporation Körniger körper und seine verwendung
JP2023113400A (ja) * 2022-02-03 2023-08-16 株式会社クラレ ポリアミド系樹脂、ポリアミド系樹脂組成物、及び成形品

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS528375B2 (de) 1973-07-02 1977-03-09
US4087390A (en) 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4093574A (en) 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
JPS5944308B2 (ja) 1976-03-23 1984-10-29 武田薬品工業株式会社 ペプタイド
US4100117A (en) 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4253998A (en) 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
JPS5692846A (en) 1979-12-27 1981-07-27 Takeda Chem Ind Ltd Tetrapeptide derivative and its preparation
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
JP2583257B2 (ja) 1986-05-05 1997-02-19 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン向性ホルモン
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
JP2861267B2 (ja) 1989-06-01 1999-02-24 萬有製薬株式会社 生理活性物質ｂｅ―１８２５７類
JPH0363232A (ja) * 1989-07-10 1991-03-19 Syntex Usa Inc 溶剤抽出方法
US5232707A (en) * 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
EP0412053B1 (de) * 1989-07-31 1995-05-10 Ciba-Geigy Ag Extraktion organischer Lösungsmittel aus geformten Stoffen durch überkritische Fluide und Gase, nahe am kritischen Punkt
GB8919726D0 (en) 1989-08-31 1989-10-11 Fujisawa Pharmaceutical Co Ws7338 substances and preparation thereof
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
CA2032559C (en) 1989-12-28 2001-11-06 Kiyofumi Ishikawa Endothelin antagonistic cyclic pentapeptides
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
CA2059380A1 (en) 1991-01-24 1992-07-25 Yiu-Kuen T. Lam Endothelin receptor antagonists isolated from microbispora
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
US5312958A (en) 1992-01-31 1994-05-17 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
EP0969016A2 (de) 1992-06-15 2000-01-05 Scios Inc. Dem Glukagon ähnliche Peptide und Insulinotropin-Derivate
US5484955A (en) 1992-07-06 1996-01-16 Takeda Chemical Industries, Ltd. Tri-higher alkyl tin azide and its use
JPH0680584A (ja) 1992-07-13 1994-03-22 Nisshin Flour Milling Co Ltd グリセンチンを有効成分とする医薬
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995005848A1 (en) 1993-08-24 1995-03-02 Novo Nordisk A/S Protracted glp-1
JPH07101877A (ja) 1993-10-04 1995-04-18 Mitsui Toatsu Chem Inc 血小板減少症治療剤
US6280771B1 (en) * 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
CA2178592C (en) * 1993-12-09 2009-07-28 Zentaris Gmbh Long-acting injection suspensions and a process for their preparation
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0668272B1 (de) 1994-01-28 2000-07-12 Takeda Chemical Industries, Ltd. Ein Verfahren zur Herstellung von Tetrazolyl-Verbindungen
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
JP3862304B2 (ja) 1994-09-09 2006-12-27 武田薬品工業株式会社 徐放性製剤
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US20010006943A1 (en) 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
ATE234625T1 (de) 1994-12-23 2003-04-15 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
JP3902272B2 (ja) 1995-09-04 2007-04-04 武田薬品工業株式会社 徐放性製剤の製造法
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JPH10265404A (ja) 1996-02-02 1998-10-06 Mitsui Chem Inc ヒト成長ホルモンを含有する医薬製剤
DE69740176D1 (de) 1996-03-01 2011-05-26 Novo Nordisk As Appetithemmendes Peptid, Zusammensetzung und Verwendung
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US5766637A (en) * 1996-10-08 1998-06-16 University Of Delaware Microencapsulation process using supercritical fluids
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP4459315B2 (ja) 1996-12-20 2010-04-28 武田薬品工業株式会社 徐放性製剤の製造法
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6391452B1 (en) * 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
EP1049486A4 (de) 1997-12-05 2006-01-04 Lilly Co Eli Glp-1 formulierungen
WO1999055310A1 (en) 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
EP1056774A1 (de) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminal verkürzte glp-1 derivate
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
EP1061946B1 (de) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
JP4758525B2 (ja) 1998-03-20 2011-08-31 武田薬品工業株式会社 生理活性ポリペプチドの徐放性製剤およびその製造法
WO1999048519A1 (en) 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
CA2270320A1 (en) 1998-04-28 1999-10-28 Patricia Lee Brubaker Novel microsphere composition
MXPA00012286A (es) 1998-06-12 2002-10-17 Bionebraska Inc Peptide-1 similar a glucagon mejora la respuesta celular beta a glucosa en sujetos con tolerancia danada de glucosa.
DE69941510D1 (de) 1998-08-10 2009-11-19 Us Gov Nat Inst Health Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6403672B1 (en) * 1998-11-30 2002-06-11 University Technology Corporation Preparation and use of photopolymerized microparticles
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
EP1992641A3 (de) 1998-12-07 2009-07-29 Ipsen Pharma GLP-1-Analoge
DE69928006T2 (de) 1998-12-22 2006-07-13 Eli Lilly And Co., Indianapolis Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
CA2372214A1 (en) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
EP1849475A1 (de) 1999-06-21 2007-10-31 Eli Lilly & Company Synergistische Verwendung von Thiazolidindionen mit glucagonartigem Peptid-1 und Agonisten davon zur Behandlung von nicht insulinabhängigen Diabetes
IT1318404B1 (it) * 2000-03-17 2003-08-25 Eurand Int Processo per la preparazione di formulazioni a rilascio accelerato conimpiego di fluidi compressi.
US6620351B2 (en) * 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6967028B2 (en) * 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
EP1369130A1 (de) * 2001-03-16 2003-12-10 Takeda Chemical Industries, Ltd. Verfahren zur herstellung eines präparats mit verzögerter freisetzung
WO2003000192A2 (en) * 2001-06-22 2003-01-03 Raveendran Poovathinthodiyil Renewable, carbohydrate based co2-philes

Also Published As

Publication number Publication date
US20040018240A1 (en) 2004-01-29
EP2062593A2 (de) 2009-05-27
AU2002224124A1 (en) 2002-06-11
EP1346722A1 (de) 2003-09-24
CA2430934C (en) 2011-06-21
US7090869B2 (en) 2006-08-15
JP2009062389A (ja) 2009-03-26
CA2430934A1 (en) 2002-06-06
WO2002043709A1 (fr) 2002-06-06
EP1346722B1 (de) 2008-12-10
DE60136958D1 (de) 2009-01-22
EP2062593A3 (de) 2011-08-17
US20060241045A1 (en) 2006-10-26
EP1346722A4 (de) 2005-08-03

Similar Documents

Publication Publication Date Title
DE60136958D1 (de) Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
DE60144104D1 (de) Membranen mit gemischter matrix und pyrolisierten kohlenstoffsiebteilchen und verfahren zur herstellung derselben
DE50103340D1 (de) Verfahren zur herstellung aktivstoffhaltiger kapseln mit ultradünner wandschicht
DE50100770D1 (de) Verfahren zur Herstellung von wasserlöslichen pi-konjugierten Polymeren
DE69500992D1 (de) WäSSRIGES POLYURETHANPOLYMER, TRENNBESCHICHTUNG, KLEBEFILM UND VERFAHREN ZUR HERSTELLUNG
DE60238346D1 (de) Verfahren zur herstellung von modifiziertem polymer, vorrichtung zur herstellung von modifiziertem polymer und modifiziertes polymer
DE60116810D1 (de) Polyhydroxyalkanoat enthaltend 3-Hydroxythienyl-Alkansäure als Monomer und ein Verfahren zur Herstellung desselben
ATE330586T1 (de) Pharmazeutische tablette und eine verfahren zu deren herstellung
DE60036560D1 (de) Fluorkohlenstoff-polymerzusammensetzungen mit hydrophilen funktionellen gruppen und verfahren zur herstellung davon
DE3884214D1 (de) Verfahren zur herstellung einer festen form mit beibehaltender freisetzung aus einer funktionellen aktiven komposition und die bei dem verfahren erhaltene dosierungsform.
DE60137386D1 (de) Phosphor-Dünnfilm, Verfahren zur Herstellung und EL-Folie
DE69617435D1 (de) Absorbierendes material, formkörper aus diesem material und verfahren zur herstellung des materials.
DE60121340D1 (de) Verfahren zur herstellung eines photochromen formteils
DE50207803D1 (de) Verfahren zur herstellung gesättigter alkohole, ketone, aldehyde und carbonsäuren
DE60227630D1 (de) Verfahren zur Herstellung von Fullerene
DE60207154D1 (de) Verfahren zur Herstellung amphoteren Polyurethanharzes, sowie daraus erhaltenes amphoteres Polyurethanharz und Harzzusammensetzung
DE50103605D1 (de) Verfahren zur Herstellung eines Spritzlings für pharmazeutische Anwendungen
ATE506083T1 (de) Verfahren zur herstellung bioabsorbierbarer wirkstofffreisetzungsvorrichtungen aus lösungsmittelgegossenen röhren
ATE337072T1 (de) Verfahren zur herstellung einer membranvorrichtung mit interner spülung
DE69008122D1 (de) Phenolnovolakharz, dessen härtungsprodukt und verfahren zur herstellung.
DE60119914D1 (de) Verfahren zur herstellung von zusammensetzungen mit beschleunigter abgabe unter verwendung von komprimierten fluiden
DE60122725D1 (de) Organosiliciumverbindungen die polyorganosiloxane mit ethylenisch ungesättigten durch imidgruppen aktivierte gruppen enthalten und verfahren zur deren herstellung
DE59310184D1 (de) Verfahren zur herstellung dünnflüssiger, lagerstabiler amphotenside
DE60002686D1 (de) Verfahren zur entformung eines durchsichtigen gegenstandes und dessen anwendung zur herstellung eines gegenstandes aus durchsichtigem kunststoff wie z.b. einer kontaktlinse
DE60035130D1 (de) Verfahren zur Herstellung eines photochromen, gehärteten Produkts

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties